Regeneron Pharmaceuticals is a US biotech company. It develops antibody drugs such as Eylea for eye diseases and, together with Sanofi, Dupixent for inflammatory diseases such as atopic dermatitis. It also does research on cancer and genetic diseases. As of Oct 11, 2026
According to the company, it is a fully integrated biotechnology company that invents, develops, manufactures and markets medicines for people with serious diseases. The business forms a single segment. The therapeutic areas range from eye diseases and allergic and inflammatory diseases to cancer, cardiovascular and metabolic diseases and rare diseases. Approved products are aimed at wet age-related macular degeneration, asthma and certain forms of lung cancer, among other conditions. The company markets individual products together with partners or licensees.
Automatically summarized from SEC annual report (10-K, filed Feb 4, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
No buy zone
There is currently no buy zone for this symbol under our Elliott rule. One only forms when the price pulls back after a strong rise.
An observation, not investment advice
Rule (4-hour candles) No entry in the zone history yet (recording since Oct 12, 2026). Zone historyThe zone history shows since when a buy zone has applied, when it was adjusted and when the price touched or left it. Recording began on Oct 12, 2026, only runs forward and fills nothing in – older zones are marked “known at start of recording” or “already existing when added”.Example: New buy zone on Oct 14, no adjustment since → “zone valid since Oct 14, 2026 · unchanged since”.More in the Academy: Lesson buy zone and Fibonacci
Weekly candles (1W) Zone known when recording started (recording since Oct 12, 2026) · Setup confirmed on Sep 28, 2026 · last changed in the Week from Oct 12, 2026 Zone historyThe zone history shows since when a buy zone has applied, when it was adjusted and when the price touched or left it. Recording began on Oct 12, 2026, only runs forward and fills nothing in – older zones are marked “known at start of recording” or “already existing when added”.Example: New buy zone on Oct 14, no adjustment since → “zone valid since Oct 14, 2026 · unchanged since”.More in the Academy: Lesson buy zone and Fibonacci
Watcher Full history: every change of the buy zone with its date.
Timeframe 1 week · As of Oct 23, 2026 · display only, the rule works on 4-hour candles
Elliott count: no count that follows the rules on this timeframe.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
Automated analysis (rule-based): the rule calculates waves and Fibonacci levels from the completed weekly candles; the chart is recalculated every day. Not investment advice. On this timeframe the chart only shows the rule setup (swing detection 2 × ATR) – the rule itself works on 4-hour candles. Axis and values: distance from the top of the buy zone in %, no prices. Fibonacci measured logarithmically (weekly candles).
On phones the drawing toolbar is hidden – drawing works better on a desktop.
Timeframe 1 day · As of Oct 26, 2026 · display only, the rule works on 4-hour candles
Elliott count: Flat (expanded), Corrective pattern (downward), C complete (2 of 3 guidelines) · B = 118% of A; C = 202% of A
provisional count The inner sub-waves cannot be seen on this timeframe – the hard Elliott rules are met, the internal structure remains open. Provisional – check the count yourself on the chart.
Note: Structure open: leg B cannot be broken down into sub-waves on this timeframe – provisional, check the count yourself on the chart.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed daily candles (recalculated every day). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 4 hours · As of Oct 27, 2026
Technical view: on this timeframe there is neither a buy zone of the rule nor an Elliott count that follows the rules. We calculate the lines automatically from the completed 4-hour candles (recalculated every hour) – for orientation, not a forecast, not a recommendation, not investment advice. Without a buy zone there is no value axis and no prices.
Timeframe 1 hour · As of Oct 27, 2026 · display only, the rule works on 4-hour candles
Elliott count: Impulse, Impulse pattern (upward), Wave 2 in progress (3 of 3 guidelines) · W2 = 65% of W1
Comparison: Rule and Elliott count agree: wave 2 in progress.
Alternative (not drawn): Flat (type known only after C), Corrective pattern (downward), C in progress (2 of 3 guidelines)
Note: Structure ambiguous: leg W1 can also be read as three- or five-part.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
Automated analysis (rule-based): the rule calculates waves and Fibonacci levels from the completed hourly candles; the chart is recalculated every hour. Not investment advice. On this timeframe the chart only shows the rule setup (swing detection 4 × ATR) – the rule itself works on 4-hour candles. Axis and values: distance from the top of the buy zone in %, no prices.
On phones the drawing toolbar is hidden – drawing works better on a desktop.
Timeframe 1 week · As of Oct 23, 2026 · from the Elliott count in the analysis chart
Weighting by guidelines met – not a probability.
Currently no wave count that follows the rules on weekly candles – so no scenarios.
Timeframe 1 day · As of Oct 26, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (2 of 3 guidelines, medium) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
provisional count The inner sub-waves cannot be seen on this timeframe – the hard Elliott rules are met, the internal structure remains open. Provisional – check the count yourself on the chart. No visible sub-waves in: B.
As long as the daily close stays above the end of C, this applies: flat countermove downward in three waves (Flat, expanded), C complete – count points to rising prices.
Invalid if the daily close is below the end of C
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
Timeframe 4 hours · As of Oct 27, 2026 · from the technical view in the analysis chart
Currently no wave count that follows the rules on 4-hour candles – so no scenarios. Technical view: Price above the 200-period average, a resistance lies above the price. Not a forecast, not investment advice.
Timeframe 1 hour · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario: ahead (3 of 3 guidelines, strong) · Alternative: behind (2 of 3, medium) Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the hourly close stays above the start of wave 1, this applies: Upward move in five waves (Impulse), wave 2 in progress (pullback) – count then points to rising prices.
Invalid if the hourly close is below the start of wave 1 (−2.1% from the top of the zone)
If that breaks, the alternative moves to the front: flat countermove downward in three waves (Flat, type known only after C), C in progress – count points to falling prices, as long as the hourly close stays below the end of B.
Invalid if the hourly close is above the end of B (+3.5% from the top of the zone)
Regeneron Pharmaceuticals · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 4, 2026.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 14.3B USD · Net income 4.5B USD · Net margin 31.4%
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
+11.0% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 11.0% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
+5.1% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +6.3% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 5.1% per year on average, but more slowly than the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
31.4% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 31.41 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 41.3%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
0.06 latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? For every 1 USD of equity there is 0.06 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
10 of 10 fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 14.3B | 4.5B | 31.4% | 41.48 | – | – |
| 2024 | Dec 31, 2024 | 14.2B | 4.4B | 31.1% | 38.34 | – | – |
| 2023 | Dec 31, 2023 | 13.1B | 4.0B | 30.1% | 34.77 | – | – |
| 2022 | Dec 31, 2022 | 12.2B | 4.3B | 35.6% | 38.22 | – | – |
| 2021 | Dec 31, 2021 | 16.1B | 8.1B | 50.2% | 71.97 | – | – |
| 2020 | Dec 31, 2020 | 8.5B | 3.5B | 41.3% | 30.52 | – | – |
| 2019 | Dec 31, 2019 | 7.9B | 2.1B | 26.9% | 18.46 | – | – |
| 2018 | Dec 31, 2018 | 6.7B | 2.4B | 36.4% | 21.29 | – | – |
| 2017 | Dec 31, 2017 | 5.9B | 1.2B | 20.4% | 10.34 | – | – |
| 2016 | Dec 31, 2016 | 4.9B | 895.5M | 18.4% | 7.70 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 4.3B | 1.3B | 30.2% | 12.23 | 0.94 | 8% |
| Q1/26 | Mar 31, 2026 | 3.6B | 727.2M | 20.2% | 6.75 | 0.94 | 14% |
| Q4/25* | Dec 31, 2025 | 3.9B | 844.6M | 21.7% | – | 0.88 | – |
| Q3/25 | Sep 30, 2025 | 3.8B | 1.5B | 38.9% | 13.62 | 0.88 | 6% |
| Q2/25 | Jun 30, 2025 | 3.7B | 1.4B | 37.9% | 12.81 | 0.88 | 7% |
| Q1/25 | Mar 31, 2025 | 3.0B | 808.7M | 26.7% | 7.27 | 0.88 | 12% |
| Q4/24* | Dec 31, 2024 | 3.8B | 917.7M | 24.2% | – | – | – |
| Q3/24 | Sep 30, 2024 | 3.7B | 1.3B | 36.0% | 11.54 | – | – |
| Q2/24 | Jun 30, 2024 | 3.5B | 1.4B | 40.4% | 12.41 | – | – |
| Q1/24 | Mar 31, 2024 | 3.1B | 722.0M | 23.0% | 6.27 | – | – |
| Q4/23* | Dec 31, 2023 | 3.4B | 1.2B | 33.8% | – | – | – |
| Q3/23 | Sep 30, 2023 | 3.4B | 1.0B | 30.0% | 8.89 | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $6.5M4 people | −$6.5M |
| 6 months | $00 people | $6.7M5 people | −$6.7M |
| 12 months | $00 people | $16.1M8 people | −$16.1M |
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
Latest news
No posts on REGN yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules